The Challenge

The emergence of multi-drug resistant bacteria presents a global public health crisis which demands the development of new antibiotics, preventive or alternative strategies, yet the R&D investment from large pharmaceutical companies is on the wane due to lack of attractiveness of investment in this therapeutic area.

Innovation is largely driven by biotech companies, and need to engage more extensively in supporting innovation with R&D stimulating policies and incentives.

Our Mission

The BEAM Alliance will work to improve the regulatory, investment, and commercial environments in Europe for research, development, approval and market viability of new products combating antimicrobial resistance.

Our Achievements so far

- One position paper
- One workshop with the European Commission
- Speaking up at DRIVE-AB
- and more to come...

Would like to join to engage policy makers with us?
Contact contact@beam-alliance.eu.